Myeloid growth factors clinical practice guidelines in oncology.
Crawford
Jeffrey
J
Duke Comprehensive Cancer Center, Duke University, Durham, NC, USA.
Althaus
Betsy
B
Armitage
James
J
Blayney
Douglas W
DW
Cataland
Spero
S
Dale
David C
DC
Demetri
George D
GD
Foran
James
J
Heaney
Mark L
ML
Htoy
Sally
S
Kloth
Dwight D
DD
Lyman
Gary H
GH
Michaud
Laura
L
Motl
Susannah
S
Vadhan-Raj
Saroj
S
Wong
Michael K
MK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D005334:Fever; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008495:Medical Oncology / Q000592:standards*; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012307:Risk Factors
D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim